Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $7.72K invested in Pasithea Therapeutics Warrants in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
12% less capital invested
Capital invested by funds: $8.8K → $7.72K (-$1.08K)
15.69% less ownership
Funds ownership: 15.69% → 0% (-16%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$242 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5 |
| 2 |
CS
Clear Street
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $6K | – | – | – |
|
|
AC
2
Armistice Capital
New York
| $845 | – | – | – |
|
|
MG
3
Marex Group
London,
| $423 | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $247 | +$242 | +14,586 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $207 | -$5 | -320 | -2% |
|
|
CS
6
Clear Street
New York
| – | -$2 | -71 | Closed |
|
KTTAW Hedge Fund Activity: Q3 2025 in Review
5 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q3 2025, worth a combined $7.72K — down 12% from $8.8K a quarter earlier.
Fund positioning in KTTAW was balanced in Q3 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $242. The largest seller was Citadel Advisors, cutting an estimated $5.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $7.72K of Pasithea Therapeutics Warrants stock for Q3 2025, down 12% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics Warrants positions in Q3 2025 and 1 closed out, a net change of 0 holders.
- The largest Pasithea Therapeutics Warrants buyer in Q3 2025 was Susquehanna International Group, an estimated $242 added.
- The largest Pasithea Therapeutics Warrants seller in Q3 2025 was Citadel Advisors, an estimated $5 sold.
Based on aggregated 13F filings for Q3 2025.